Mainz Biomed N.V. (MYNZ) Stock Price, Quote & News

Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fishe...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 49 6131 554 2860

Website: mainzbiomed.com

Address:

Robert Koch Strasse 50, Mainz, Germany

Bleachedsmiles Aug. 4 at 2:36 PM

$MYNZ why would they even start diluting at this price range when they’ve apparently just started government funding? They know it will just tank the stock further …almost as if they want another RS Time to announce yet another partnership

0 · Reply

Righon23420 Aug. 4 at 1:22 PM

$MYNZ up from here!

0 · Reply

CumulativeChaser Aug. 4 at 9:34 AM

$LUMN $PARA $BTCM $MYNZ '

1 · Reply

PremiumSqueezers Aug. 4 at 8:23 AM

Ticker GYRO is exploding in pre-market!! Could GYRO be todays big squeeze?! news just released.. 700k shares float.. watchers on GYRO are growing very fast. Would not be surprised if GYRO is todays big 300% runner. 20$+ break could send her parabolic! $COMM $AI $MYNZ $WINT movers

0 · Reply

peterb030 Aug. 3 at 2:31 PM

$MYNZ 1.36:40+0.034 $ cents

0 · Reply

peterb030 Aug. 3 at 2:29 PM

$MYNZ November 29, 2024 BERKELEY, US and MAINZ, Germany – November 29, 2024 – Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by the Board of Directors of the Company pursuant to shareholder approval granted at its Extraordinary Shareholders Meeting on November 20, 2024.

1 · Reply

twin_dad Aug. 3 at 1:08 AM

$MYNZ

0 · Reply

peterb030 Aug. 2 at 2:32 PM

$MYNZ 📢🤡

0 · Reply

peterb030 Aug. 2 at 2:29 PM

$MYNZ who's that donkey that throws his soap on the floor to pick it up.... again. How does it feel fcked by Mynz again🤣

0 · Reply

peterb030 Aug. 2 at 2:26 PM

$MYNZ fooled again. Only donkey's investing in this so called German compagny based in an office in a builing with other company's and is actually a Dutch compagny.... Very

0 · Reply

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

Jul 15, 2025, 8:01 AM EDT - 20 days ago

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

Jun 25, 2025, 8:01 AM EDT - 5 weeks ago

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

Jun 10, 2025, 9:01 AM EDT - 7 weeks ago

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

May 19, 2025, 8:01 PM EDT - 2 months ago

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

May 16, 2025, 8:01 AM EDT - 2 months ago

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Apr 29, 2025, 8:01 AM EDT - 3 months ago

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Apr 28, 2025, 8:01 AM EDT - 3 months ago

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

Mar 27, 2025, 9:01 AM EDT - 4 months ago

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mar 13, 2025, 8:01 AM EDT - 5 months ago

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Mar 3, 2025, 8:01 AM EST - 5 months ago

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Feb 20, 2025, 8:01 AM EST - 5 months ago

Mainz Biomed Expands into Switzerland with labor team w

Feb 11, 2025, 8:01 AM EST - 6 months ago

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Jan 27, 2025, 8:01 AM EST - 6 months ago

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Jan 21, 2025, 8:01 AM EST - 6 months ago

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Dec 19, 2024, 8:01 AM EST - 8 months ago

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Dec 16, 2024, 5:00 PM EST - 8 months ago

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Dec 12, 2024, 8:00 PM EST - 8 months ago

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Dec 3, 2024, 2:40 PM EST - 8 months ago

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

TMO

Nov 29, 2024, 8:45 AM EST - 8 months ago

Mainz Biomed Announces Stock Split

Oct 21, 2024, 8:01 AM EDT - 10 months ago

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 8:01 AM EDT - 10 months ago

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Oct 1, 2024, 8:01 AM EDT - 10 months ago

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Sep 18, 2024, 8:01 AM EDT - 11 months ago

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Sep 4, 2024, 4:01 AM EDT - 11 months ago

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Jul 25, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Jul 9, 2024, 3:01 AM EDT - 1 year ago

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Jul 2, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Provides Half Year 2024 Corporate Update

Jun 3, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

May 31, 2024, 5:01 PM EDT - 1 year ago

Mainz Biomed Reports Results of 2024 Annual General Meeting

May 28, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

May 20, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

May 7, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

Apr 25, 2024, 9:29 AM EDT - 1 year ago

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Apr 9, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Full Year 2023 Financial Results

Mar 19, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Mar 18, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mar 12, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mar 5, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Feb 27, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Feb 22, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

Feb 21, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

Feb 6, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany

Jan 11, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

Jan 9, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Provides Year-End Corporate Review 2023

Dec 19, 2023, 3:39 PM EST - 1 year ago

Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study

Dec 19, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

Dec 12, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

Dec 5, 2023, 9:01 AM EST - 1 year ago

Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

Nov 29, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed's Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast

Bleachedsmiles Aug. 4 at 2:36 PM

0 · Reply

Righon23420 Aug. 4 at 1:22 PM

$MYNZ up from here!

0 · Reply

CumulativeChaser Aug. 4 at 9:34 AM

$LUMN $PARA $BTCM $MYNZ '

1 · Reply

PremiumSqueezers Aug. 4 at 8:23 AM

0 · Reply

peterb030 Aug. 3 at 2:31 PM

$MYNZ 1.36:40+0.034 $ cents

0 · Reply

peterb030 Aug. 3 at 2:29 PM

1 · Reply

twin_dad Aug. 3 at 1:08 AM

$MYNZ

0 · Reply

peterb030 Aug. 2 at 2:32 PM

$MYNZ 📢🤡

0 · Reply

peterb030 Aug. 2 at 2:29 PM

$MYNZ who's that donkey that throws his soap on the floor to pick it up.... again. How does it feel fcked by Mynz again🤣

0 · Reply

peterb030 Aug. 2 at 2:26 PM

$MYNZ fooled again. Only donkey's investing in this so called German compagny based in an office in a builing with other company's and is actually a Dutch compagny.... Very

0 · Reply

APEDM Aug. 2 at 4:11 AM

$MYNZ what happened

1 · Reply

walkinghome Aug. 1 at 9:31 PM

$MYNZ Link to offering: https://s3.amazonaws.com/sec.irpass.cc/2642/0001213900-25-069318.htm

0 · Reply

LongBallBarn Aug. 1 at 7:09 PM

$MYNZ

0 · Reply

patientboy Aug. 1 at 6:59 PM

$MYNZ added some shares Discount price 🔥✈️

0 · Reply

_802016493_ Aug. 1 at 4:11 PM

$MYNZ BTD

0 · Reply

GerRookie Aug. 1 at 4:01 PM

$MYNZ Anyone know anything about that drop in share price? I’m at a loss…Communication isn’t their strength anyway…

4 · Reply

walkinghome Aug. 1 at 3:48 PM

$MYNZ from schwab:

0 · Reply

Chaine Aug. 1 at 3:24 PM

$MYNZ very near all time low..

0 · Reply

Panicmode Aug. 1 at 3:23 PM

$MYNZ remember all those bots spamming everywhere how great this play is.. 🤣🤣🤣🤣

0 · Reply

Chaine Aug. 1 at 3:23 PM

$MYNZ what the hell is going on here.. I taught this german Cie was going to make us all rich. am losing 74% of my investment and seems like the recovery will take a ling time at this pace.

1 · Reply

safwan09 Aug. 1 at 3:20 PM

$MYNZ what the 🤷

0 · Reply

walkinghome Jul. 30 at 2:49 PM

$MYNZ i have not been able to much dd on this. very little information. even the website does not give much insight other than the possiblity of German health markets. I like the screening slides. for colon and pancreatis. and think there is a real need. there must be some analysis out there please share a sight if possible. anyone Bueller? want to be bullish

1 · Reply

Market Cap	6.09M
Revenue (ttm)	890,000.00
Net Income (ttm)	-21.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,432.58%
Debt to Equity Ratio	0.18

Volume	661,730
Avg Vol	148,424
Day's Range	N/A - N/A
Shares Out	4.58M
Stochastic %K	3%
Beta	0.24
Analysts	Strong Sell
Price Target	$14.00